



University of
Salford
MANCHESTER

FRI0592-HPR Work rehabilitation in inflammatory arthritis: A pilot randomised controlled trial

Hammond, A, Prior, Y, O'Brien, R., Woodbridge, S. and Radford, K.

<http://dx.doi.org/10.1136/annrheumdis-2014-eular.5378>

Title	FRI0592-HPR Work rehabilitation in inflammatory arthritis: A pilot randomised controlled trial
Authors	Hammond, A, Prior, Y, O'Brien, R., Woodbridge, S. and Radford, K.
Publication title	Annals of the Rheumatic Diseases (ARD)
Publisher	BMJ Publishing Group
Type	Article
USIR URL	This version is available at: http://usir.salford.ac.uk/id/eprint/33509/
Published Date	2014

USIR is a digital collection of the research output of the University of Salford. Where copyright permits, full text material held in the repository is made freely available online and can be read, downloaded and copied for non-commercial private study or research purposes. Please check the manuscript for any further copyright restrictions.

For more information, including our policy and submission procedure, please contact the Repository Team at: library-research@salford.ac.uk.

Hammond A, Prior Y, O'Brien R, Woodbridge S, Radford K (2014) Work rehabilitation in inflammatory arthritis: a pilot randomised controlled trial. *Annals of the Rheumatic Diseases*, 73 (Suppl 2): 1209 doi:10.1136/annrheumdis-2014-eular.5378

Background: Work problems are common in people with inflammatory arthritis (IA): with 28-40% of people with rheumatoid arthritis (RA) stopping work in 5y of diagnosis. There is little research into effectiveness of job retention vocational rehabilitation (JR-VR) for employed people with IA. Brief JR-VR led to significantly fewer job losses at 3.5 years in the USA (Allaire et al, 2003) and a UK pilot trial demonstrated 6m improvements in work instability and work satisfaction (Macedo et al, 2009).

Objectives: To conduct a pilot randomised controlled trial (RCT) evaluating a JR-VR intervention with employed people with IA, to facilitate planning a full RCT.

Method: Participants with IA were recruited from 6 Rheumatology departments and randomised to VR (delivered by Rheumatology OTs with VR training) or a control group. Both groups received written self-help information about managing work problems. The VR group could receive up to 6h JR-VR, including a work visit. Presenteeism outcomes included: RA-Work Instability Scale (RAWIS:0-23), Work Limitations Questionnaire Productivity Loss (WLQPL: %), Work Activities Limitations Scale (WALS:0-33). Absenteeism was measured using monthly work diaries. Health outcomes included: SF12v2 Physical component (SF12-PC), pain and fatigue VAS (0-100). Mean (SD) change scores and effect sizes were calculated.

Results: 213 eligible employed patients with IA were identified, of whom 55 (26%) participated (34 with RA): 13M, 42F; aged 49y (SD 8.8); 7.9y (SD 8.9) disease duration; 33 worked full-time; job types were professional (27%), associated professional/skilled (15%), partly skilled/admin/caring/retain (53%), unskilled (5%). Both groups were comparable at baseline (see Table). At 9m: effect sizes were moderate to large for changes in work and health outcomes in the JR-VR group and none to small in the control group; %working days lost due to sickness: JR-VR =9.6% (SD 13.6); control = 20% (SD 27.1). JR-VR lasted on average 3.08 (SD 1.8) hours and cost £74.98 (SD £46.80) per patient.

	JR-VR 0m	JR-VR change 9m	JR-VR Effect Size	Control 0m	Control change 9m	Control Effect size
RAWIS	16.2 (5)	-3.9 (5.3)	-0.74	15 (5.7)	-1 (3.5)	-0.19
WLQPL	10.9 (4.9)	-3.2 (3.7)	-0.62	11.2 (5.6)	-0.4 (4.3)	-0.08
WALS	12.8 (5.3)	-2.2 (4.5)	-0.39	12.7 (6.2)	0.6 (6.0)	0.11
SF12PC	32.5 (8.3)	5.3 (11.11)	0.58	32.6 (10.1)	2.5 (8.3)	0.27
Pain	50.4 (22.6)	-12 (27)	-0.50	45.7 (25.7)	0.1 (21.8)	0
Fatigue	60 (22.4)	-5.3 (22.9)	-0.20	58.7 (30.1)	5.4 (26.4)	0.21
Health	50.9 (18.4)	-14.6 (28.8)	-0.71	48.7 (23.1)	-3.9 (15.8)	-0.19

Conclusions: This pilot suggests brief JR-VR provided by Rheumatology OTs can improve presenteeism, absenteeism and health status, indicating a RCT is warranted. Recruitment was problematic, with many not consenting. Potential reasons include: fear about employers (in a recession) learning they have arthritis; concerns about time out of work attending VR; and not perceiving VR is needed as yet. JR-VR intends to prevent work problems. Support is needed to enable employed people with IA and work problems to attend JR-VR.

References: Allaire SH, Li W, La Valley MP (2003). *Arthritis Rheum* 48(11): 3212–3218; Macedo A et al (2009). *Arthr Care Res* 61(11):1522-1530

Acknowledgements: This study was funded by Arthritis Research UK.

Disclosure of Interest: None declared

